Obesity;Obesidade

Revista Brasileira de Medicina

Volumn 66, Issue DECEMBER SPEC. IS, 2009, Pages 100-108

  De Melo, Maria Edna ^a   Mancini, Marcio C ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Liga de Obesidade Infantil da FMUSP   (Brazil)

Author keywords

Diagnosis; Obesity; Treatment

Indexed keywords

AMFEPRAMONE; BIOMAG; DESOBESI M; DUALID S; FENPROPOREX; FLUOXETINE; HIPOFAGIN S; INIBEX S; LIPIBLOCK; MAZINDOL; MODERINE; PLACEBO; PLENTY; REDULIP; RIMONABANT; SACIETTE; SERTRALINE; SIBUS; SIBUTRAMINE; SIBUTRAN; SIGRAN; SLENFIG; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VAZY;

ARTICLE; BARIATRIC SURGERY; BLOOD CLOTTING DISORDER; BODY MASS; BULIMIA; CLINICAL TRIAL; COGNITIVE THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DEFECATION; DEGENERATIVE DISEASE; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FATTY LIVER; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; IMPEDANCE; INSOMNIA; KINESIOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREVALENCE; SIDE EFFECT; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 77349124688     PISSN: 00347264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Seidell JC. Epidemiology: Definition and Classification of Obesity. In: Clinical Obesity, Kopelman PG & Stock MJ Eds., Blackwell Science, London, pp. 1-17,1998.
2. http://www.cdc.gov/obesity/childhood/defining.html
3. Farooqi IS. Monogenic human obesity. Front Horm Res. 2008; 36:1-11.
4. Danford LC, Schoeller DA & Kushner RF. Comparison of two bioeletrical impedance models for total body water measurements in children. Ann Hum Biol 1992; 19:603-7.
5. Sims EAH & Berchtold P. Obesity and hypertension: mechanisms and implications for management. JAMA 1982; 247:49-52.
6. Bray GA. Complications of obesity. Ann Intern Med 1985; 103:1052-62.
7. Garrison RJ, Kannel WB, Stokes III J & Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham Offspring Study. Prev Med 1987; 16:235-51.
8. Kissebah AH & Peiris AN. Biology of regional body fat distribution. Relationship to non-insulin-dependent diabetes mellitus. Diab Metab Rev 1989; 15:83-109.
9. Vague J. La différenciation sexuelle, facteur déterminant des formes d'obésité. Presse Med 1947; 30:339-40.
10. Després JP, Prud'homme D, Pouliot MC et al. Estimation of deep abdominal adipose-tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991 ; 54:471-7.
11. Sjǒstrǒm L, Kvist H, Cederblad A & Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 4OK, and tritium. Am J Physiol 1986; 250:E736-45.
12. Kissebah AH & Krakower GR. Regional adiposity and morbidity. Physiolog Rev 1994; 74:761-811.
13. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
14. Tchernof A, Lamarche B et al. The dense LDL phenotipe: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19:629-37.
15. Simopoulos A & Van Italie T. Body weight, health and longevity. Ann Intern Med 1984; 100:285-95.
16. Manson J, Stampfer M et al. Body weight and longevity. A reassessment. JAMA 1987; 257:353-8.
17. Garn S, Leonard W & Hawthorne V. Three limitations of the body mass index. Am J Clin Nutr 1986; 44:996-7.
18. Feinleb M. Epidemiology of obesity in relation to health hazards. Ann Intern Med 1985; 103:1019-24.
19. Robinson S & Franks S. Obesity, Infertility, Contraception and Pregnancy. In: Clinical Obesity, Kopelman PG & Stock MJ Eds., Blackwell Science, London, 1998, pp. 226-47.
20. Manson J, Willett W et al. Body weight and mortality among women. N Engl J Med 1995; 333:677-85.
21. Kannel W, D'Agostino R & Belanger A. Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 1992; 2:457-66.
22. Ditschunneit H, Flechtner-Mors M & Adler G. Fibrinogen in obesity before and after weight reduction. Obesity Res 1995; 3:43-8.
23. Van Gaal L, Zhang A, Steijaert M & De Leeuw I. Human obesity: from lipid abnormalities to lipid oxidation. Int J Obesity 1995; 19(suppl.3):S21-26.
24. Folsom A, Burke G et al. Relation of body fatness and its distribution to cardiovascular risk factors in young black and whites. The role of insulin. Am J Epidemiol 1989; 130:911-24.
25. Friedman G, Selby J et al. Precursors of essential hypertension: body weight, alcohol and salt use, and parental history of hypertension. Prev Med 1988; 17:387-402.
26. de Sousa AG, Cercato C, Mancini MC, Halpern A. Obesity and obstructive sleep apnea-hypopnea syndrome. Obes Rev. 2008; 9(4):340-54.
27. Barbara L, Sama C, Labate AMM et al. A population study on the prevalence of gallstone disease: the Sirmione study. Hepatol 1987; 7:913-7.
28. Clain D & Lefkowitch J. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am 1987; 16:239-52.
29. Swanson C, Brinton L, Taylor P, Licitra L, Ziegler R & Schairer C. Body size and breast cancer risk assessed in women participating in the breast cancer detection demonstration project. Am J Epidemiol 1989; 130:1133-41.
30. Austin H, Austin J, Partridge E et al. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51:568-72.
31. Demark-Wahnefried W, Paulson D et al. Body dimension differences in men with and without prostate cancer. J Nat Cancer Inst 1992; 84:1363-4.
32. Young T, Palta M, Dempsey J, Skatrud J, Webber S, Badr S. The occurence of sleep disordered breathing among middle aged adults. N Engl J Med 1993; 328:1230-1235.
33. Young T, Finn L, HIa M, Morgan B, Palta M. Snoring as Part of a Dose-Response Relationship Between Sleep-Disordered Breathing and Blood Pressure. Sleep 1996; 19 (10):S202-206.
34. Mancini MC & Aloe F. Obesidade, Apnéia Obstrutiva do Sono e Distúrbios Respiratorios. In: Obesidade, Halpern A, Matos AFG, Suplicy H, Mancini MC & Zanella MT, Ed. Lemos, São Paulo, 1998, pp. 153-170.
35. Cole TJ, Freeman JV & Preece MA. Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-9.
36. Chan JM, Stampfer MJ, Ribb EM et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in man. Diabetes Care 1994; 17:961-9.
37. Finer N. Clinical Assessment, Investigation and Principles of Management: Realistic Weight Goals. In: Clinical Obesity, Kopelman PG & Stock MJ Eds., Blackwell Science, London, 1998, pp. 350-376.
38. Wilson GT & Fairburn CG. Cognitive treatments for eating disorders. J Consulting Clin Psychol 1993; 61:261-9.
39. Tremblay A & Buemann B. Exercise-training, macronutrient balance and body weight control. Int J Obesity 1995; 19:79-86.
40. Tremblay A, Simoneau J & Bouchard C. Impact of exercise intensity on body fatness and skeletal muscle metabolism. Metabolism 1994; 43:814-8.
41. Thomas PR (ed.). Weighing the Options: Criteria for Evaluating Weight-Management Programs. National Academy Press: Washington DC. 1996.
42. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996; 276:1907-1915.
43. Mancini MC. Tratamento Farmacologico da Obesidade: Medicamentos Calorigânicos. In: Obesidade, Halpern A, Mates AFG, Suplicy H, Mancini MC & Zanella MT, Ed. Lemos, São Paulo, pp. 297-303,1998.
44. Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metabol. 2006; 50(2):377-89.
45. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the Risk of Hemorrhagic Stroke. N Engl J Med. 2000; 343:1826-1832.
46. Cercato C, Roizenblatt VA, Leança CC, Segal A, Lopes Filho AP, Mancini MC, Halpern A. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects. Int J Obes. 2009; 33(8):857-65.
47. Connoley IP, Heal DJ, Stock MJ. A study in rats of the effects of sibutramine on food intake and thermogenesis. Br J Pharmacol. 1995; 114(suppl.):388P.
48. Halford JCG, Heal DJ, Blundell JE. Effects in the rat of sibutramine on food intake and the behavioural satiety sequence. Br J Pharmacol: 1995; 114 (suppl.):387P.
49. Connoley IP, Uu Y-L, Frost I, et al. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999; 126:1487-1495.
50. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21(suppl.3):S12-S23.
51. Zhi J, Melia AT, Funk C, et al. Metabolic profile of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol. 1996; 36:1006-1011.
52. Halpern A, Mancini MC. Diabesity: are weight loss medications effective? Treat Endocrinol. 2005; 4(2):65-74.
53. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces doserelated weight loss. Obesity Res. 1999; 7:189-198.
54. Sjǒstrǒm L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-172.
55. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21:1288-1294.
56. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction In obese subjects treated for 2 years with orlistat. JAMA 1999; 281:235-242.
57. Garrido Jr. AB, Matielli J.D. Tratamento Cirúrgico do Paciente Obeso. Obesidade e Síndrome Metabólica para o Clínico. Halpern A, Mancini M. Ed. Roca, São Paulo, pp. 267-290, 2009.
58. Sjǒstrǒm L, Narbro K, Sjǒstrǒm CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 23;357(8):741-52.
59. Sjǒstrǒm L, Gummesson A, Sjǒstrǒm CD, et al. Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009; 10(7):653-62.